Press Releases

Circassia Completes Recruitment for Cat Allergy Treatment Pivotal Phase III Study

Click here to download full press release – Study on track to report in H1 2016 – – 1,409 subjects randomised; 19% above target – Oxford, UK – 8 January 2015: Circassia Pharmaceuticals plc (“Circassia”...

View details

Circassia Announces Top-Line Results from Ragweed Allergy Treatment Phase IIb Chamber Study

Click to download full press release Oxford, UK – 8 December 2014: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on allergy, today announces results from a phase IIb...

View details

Circassia Interim Management Statement

Click here to download November 2014 Interim Management Statement – Strong operational progress; clinical programmes on track – – Encouraging results from third season follow-up study in grass allergy – Oxford, UK – 11 November...

View details

Interim Results for the Six Months Ended 30 June 2014

Click here to download the full 2014 interim results statement — Successfully raised over £200 million in landmark IPO — — Fully-funded to bring to market the first of a new generation of allergy immunotherapies...

View details

Circassia Announces Results from House Dust Mite Allergy Treatment Phase IIb Two-Year Follow-up Study

Click here to download full press release Oxford, UK – 13 June 2014: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a clinical-stage specialty biopharmaceutical company, today announces positive top-line results from a two-year...

View details

Notice of Interim Results

Oxford, UK – 3 June 2014: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a clinical-stage specialty biopharmaceutical company, will be announcing its interim results for the six months ended 30 June 2014 on...

View details

Interim management statement

May 2014 Interim Management Statement Oxford, UK – 19 May 2014: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a clinical-stage specialty biopharmaceutical company, today publishes its interim management statement for the period from...

View details

Circassia Appoints Paul R Edick to its Board of Directors

OXFORD, UK – 17 October 2013 – Circassia Ltd, a specialty biopharmaceutical company focused on developing world-class immunotherapies, today announced the appointment of Paul R Edick to its Board.  Mr Edick is currently CEO of...

View details

Circassia’s Rapid Grass Allergy Treatment Achieves Significant Symptom Reduction During Hay Fever Season

OXFORD, UK – 1 October 2013 – Circassia Ltd, a specialty biopharmaceutical company focused on developing world-class immunotherapies, today announced successful results from a large phase II clinical study of its ToleroMune® grass allergy treatment...

View details

Circassia Appoints Dr Francesco Granata as Chairman

OXFORD, UK – 25 September 2013 – Circassia Ltd, a specialty biopharmaceutical company focused on developing world-class immunotherapies, today announced the appointment of Dr Francesco Granata as Non-Executive Chairman.  Dr Granata is Executive in Residence...

View details